Understand the source comparison
Comparison Table: Follistatin-344 vs Other Myostatin Inhibitors
The follistatin-344 safety profile can be contextualized by comparing it to other investigational myostatin inhibitors that have advanced further in clinical development. The table below summarizes key safety and regulatory distinctions. | Compound | Mechanism
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The follistatin-344 safety profile can be contextualized by comparing it to other investigational myostatin inhibitors that have advanced further in clinical development. The table below summarizes key safety and regulatory distinctions.
- | Compound | Mechanism of Action | Highest Clinical Trial Phase | Most Common Adverse Events | Serious Adverse Events Reported | Regulatory Status | Professional Assessment ||—|—|—|—|—|—|| Follistatin-344 (AAV-delivered) | Binds and neutralizes myostatin, activin, BMPs | Phase IIa | Injection-site pain, transient CK elevation | None in published trials (n<150) | Investigational; no FDA approval | Limited human data; theoretical risks uncharacterized. Not suitable for general clinical use. || Bimagrumab (monoclonal antibody) | Blocks activin type II receptor | Phase III | Muscle spasms, diarrhea, mild acne | Rare liver enzyme elevations | Discontinued after Phase III failure | Advanced safety data; efficacy did not meet endpoints. Well-tolerated but clinically ineffective. || Landogrozumab (monoclonal antibody) | Neutralizes myostatin specifically | Phase II | Injection-site reactions, headache | None reported in Phase II | Development halted | Narrow mechanism; fewer off-target concern